ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Zyprexa (olanzapine) by Year
Zyprexa (olanzapine) — Outside U.S. revenue ($M) [legacy] ($M)
Eli Lilly Zyprexa (olanzapine): $114M in FY2024, down 92.9% from a year earlier. That is the lowest of the 9 years on record here. No newer figure appears in the documents we track.
Latest, FY2024
114
Period ended Dec 31, 2024
Change on a year earlier
-92.9%
1,615 in FY2023
History
9 years
Since FY2016
Sources
7
Documents cited below
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-19) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zyprexa (olanzapine) — Outside U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 114 | -92.9% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 1,615 | +427.0% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 307 | -21.6% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 391 | +8.4% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 361 | -4.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 378 | -13.2% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 435 | -14.0% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 506 | -22.9% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 656 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Zyprexa (olanzapine) ($M), annual FY2016–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zyprexa-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.